Aerovate Historical Valuation

AVTE Stock  USD 2.56  0.03  1.19%   
Some fundamental drivers such as market cap or Aerovate Therapeutics enterprice value can be analyzed from historical perspective to project value of the company into the future. Some investors analyze Aerovate Therapeutics valuation indicators such as Working Capital of 0.0 or Enterprise Value of 407.8 M to time the market or to short-sell their positions based on the trend in valuation ratios. It is a perfect tool to project the direction of Aerovate Therapeutics's future value.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.

About Aerovate Valuation Data Analysis

Valuation is the financial process of determining what Aerovate Therapeutics is worth. Aerovate Therapeutics valuation ratios put that insight into the context of a company's share price, where they serve as useful tools for evaluating and utilizing investment potential. Aerovate Therapeutics valuation ratios help investors to determine whether Aerovate Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Aerovate with respect to the benefits of owning Aerovate Therapeutics security.

Aerovate Therapeutics Valuation Data Chart

As of December 19, 2024, Market Cap is expected to decline to about 423.9 M. In addition to that, Enterprise Value is expected to decline to about 407.8 M

Enterprise Value

Enterprise Value (or EV) is usually referred to as Aerovate Therapeutics theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Aerovate Therapeutics debt, but would also pocket its cash. Enterprise Value is more accurate representation of Aerovate Therapeutics value than its market capitalization because it takes into account all of Aerovate Therapeutics existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Aerovate Therapeutics is a strong investment it is important to analyze Aerovate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aerovate Therapeutics' future performance. For an informed investment choice regarding Aerovate Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.99)
Return On Assets
(0.49)
Return On Equity
(0.82)
The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aerovate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.